Pfizer Inc. (PFE)
Largest Insider Buys in Sector
PFE Stock Price History Chart
PFE Stock Performance
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, …
Insider Activity of Pfizer Inc.
Over the last 12 months, insiders at Pfizer Inc. have bought $107,641 and sold $147,714 worth of Pfizer Inc. stock.
On average, over the past 5 years, insiders at Pfizer Inc. have bought $420,246 and sold $13.84M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Gottlieb Scott (director) — $107,641.
The last purchase of 1,000 shares for transaction amount of $28,240 was made by Gottlieb Scott (director) on 2024‑10‑30.
List of Insider Buy and Sell Transactions, Pfizer Inc.
| 2024-10-30 | director | 1,000 <0.0001% | $28.24 | $28,240 | -6.31% | |||
| 2024-08-13 | Sale | SVP & Controller | 5,154 <0.0001% | $28.66 | $147,714 | 0.00% | ||
| 2023-12-15 | director | 3,000 <0.0001% | $26.47 | $79,401 | +6.15% | |||
| 2023-05-08 | director | 1,000 <0.0001% | $38.58 | $38,580 | -20.27% | |||
| 2023-05-05 | director | 1,000 <0.0001% | $38.42 | $38,425 | -19.88% | |||
| 2023-03-15 | Sale | SVP & Controller | 9,912 0.0002% | $40.02 | $396,678 | -14.70% | ||
| 2022-06-07 | Sale | SVP & Controller | 4,218 <0.0001% | $53.96 | $227,603 | -14.86% | ||
| 2022-05-13 | Sale | Executive Vice President | 1,408 <0.0001% | $49.84 | $70,175 | -5.33% | ||
| 2022-05-13 | Sale | SVP & Controller | 4,000 <0.0001% | $50.50 | $202,000 | -5.33% | ||
| 2022-05-12 | Sale | Executive Vice President | 38,273 0.0007% | $49.41 | $1.89M | -6.07% | ||
| 2022-05-12 | Sale | Executive Vice President | 32,908 0.0006% | $50.00 | $1.65M | -6.07% | ||
| 2022-05-11 | Sale | President R&D | 32,015 0.0006% | $49.31 | $1.58M | -3.29% | ||
| 2021-12-03 | Sale | Executive Vice President | 38,000 0.0007% | $53.42 | $2.03M | -5.95% | ||
| 2021-12-02 | Sale | Executive Vice President | 82,720 0.0015% | $54.26 | $4.49M | -3.77% | ||
| 2021-11-26 | Sale | Executive Vice President | 88,616 0.0016% | $54.52 | $4.83M | -5.48% | ||
| 2021-11-26 | Sale | Executive Vice President | 80,000 0.0014% | $54.37 | $4.35M | -5.48% | ||
| 2021-11-12 | Sale | Group President | 52,340 0.0009% | $49.60 | $2.6M | +2.89% | ||
| 2021-11-11 | Sale | Group President | 300,000 0.0053% | $50.06 | $15.02M | +1.93% | ||
| 2021-11-11 | Sale | President R&D | 119,328 0.0021% | $50.29 | $6M | +1.93% | ||
| 2021-08-13 | Sale | SVP & Controller | 3,322 <0.0001% | $48.30 | $160,453 | +6.47% |
Insider Historical Profitability
| Gottlieb Scott | director | 10000 0.0002% | $25.05 | 6 | 0 | <0.0001% |
| SIMMONS DAVID S | Business Unit President | 134404 0.0024% | $25.05 | 1 | 0 | +21.17% |
| SUSMAN SALLY | Executive Vice President | 89575 0.0016% | $25.05 | 1 | 11 | <0.0001% |
| BURT ROBERT N | director | 12200 0.0002% | $25.05 | 1 | 0 | +18.59% |
| BLAYLOCK RONALD E | director | 13000 0.0002% | $25.05 | 1 | 0 | +2.07% |
Institutional Investor Ownership
| The Vanguard Group | $14.08B | 8.95 | 507.25M | +0.14% | +$20.44M | 0.26 | |
| BlackRock | $11.96B | 7.61 | 431.12M | -0.32% | -$38.44M | 0.26 | |
| State Street | $8.07B | 5.13 | 290.7M | +1.12% | +$89.22M | 0.33 | |
| Wellington Management Company | $4.93B | 3.14 | 177.7M | -25.71% | -$1.71B | 0.84 | |
| Charles Schwab | $3.37B | 2.16 | 122.24M | +17.26% | +$495.97M | 0.73 |